IL-17 inhibitor | 2 Minute Medicine

Hidradenitis suppurativa associated with increased risk of subclinical atherosclerosis

Bimekizumab safe and effective for treatment of moderate-to-severe hidradenitis suppurative

June 13, 2024

1. Significantly more patients in the bimekizumab group than placebo reported improved clinical response at week 16. 2. Treatment-related adverse ...

#VisualAbstract: IL-17 inhibitors are associated with higher treatment persistence than TNF inhibitors in patients with psoriasis and psoriatic arthritis

byKathleen Lau

April 7, 2022

0

#VisualAbstract Risk of serious infection in patients with moderate to severe psoriasis is associated with the type of biologic treatment

byKathleen Lau

August 13, 2021

0

Quick Take: Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent)

Sonelokimab 120 mg or less showed significant clinical benefit over placebo in patients with plaque psoriasis

byNeel Mistryand1 others

May 5, 2021

0

1. At 12 weeks, the proportion of patients with an IGA score of 0 or 1 was significantly greater in ...

#VisualAbstract: Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)

byConstance Wu

January 5, 2020

0

1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with ...

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X)

byDonna Leetand1 others

December 22, 2019

0

1. Ixekizumab, an IL-17 inhibitor, elicits disease response in patients with non-radiographic active axial spondyloarthritis who have failed treatment with ...

2 Minute Medicine Rewind December 9, 2019

byDonna Leetand2 others

December 19, 2019

0

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 1. Obeticholic ...

Tag: IL-17 inhibitor